INEOS has long been passionate about public health, and its trio of owners Sir Jim Ratcliffe, John Reece and Andy Currie are determined to join the fight to mitigate AMR for future generations. After seeing the impact of a Covid-19 pandemic the world was not prepared for, they decided that the time to act this was now, and have provided £100m seed funding to found the Ineos Oxford Institute. This represents an unprecedented corporate donation to the field of AMR, and will create a new model of industry-academic collaboration at Oxford between one of the top research universities in the world, and the UK’s biggest private company. 

The successful development of antibiotics was the result of unparalleled collaboration during World War II, between academia, industry and government- and we truly believe that such levels of collaboration are again vital to tackling AMR before it’s too late. 

INEOS is famous for delivering visionary large-scale projects ranging from the creation of 6 global hand sanitizer plants in 10 days, the development of the most energy-efficient ethylene cracker in Europe, and the performance management of the first sub-two hour marathon time. In its 22 years it has become the UK’s largest private company, managing a complex network of businesses across 194 global sites. While it will have no bearing on the academic agenda of the IOI, INEOS intends to work with the University of Oxford to support the organisation’s growth and development on the global stage in order to achieve its research aims and recreate the advances achieved at the beginning of antibiotic development. 

Long committed to philanthropy in the public health space, INEOS has already funded initiatives such as The Daily Mile, which aims to get the world’s children active every day, and the UK’s Defence and Military Rehabilitation Centre, supporting rehabilitation for wounded soldiers. INEOS also supports local health causes around its global network of 194 sites, and provides health and fitness training for its 26,000 employees. AMR will be the primary focus of its future philanthropic efforts.